| Currently, we are conducting a randomized, double blind placebo controlled Phase II clinical trial on our nasal spray in Helsinki, Finland, that we estimate will take at least six months to complete.
138 patients meeting the criteria for Binge Eating Disorder were randomly selected from over 900 applicants wanting to participate in our trials. The nasal spray adheres to international safety standards.
The opioid antagonist in our nasal spray—naloxone—should be well suited to treating Binge Eating Disorder, as it remains in the brain for 2 hours, which is the duration of a typical binge. Long-lasting opioid antagonists like naltrexone and nalmefene are sufficient for treating alcoholism and drug addiction; however, side effects include a loss of interest in exercise, which should not occur with naloxone. Naloxone works to selectively remove only unhealthy eating responses.
|
